Search Results - "Eisner, Joel Robert"

Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model by Moore, William R., Norris, John D., Wardell, Suzanne, Eisner, Joel Robert, Hoekstra, William J., Schotzinger, Robert J., McDonnell, Donald P.

“…Abstract only 263 Background: MDV3100 inhibits binding of androgens to AR and abiraterone is known to block androgen production through CYP17 inhibition; both…”
Get full text

Development of a novel RNA-based immune checkpoint inhibitor response signature (ICI-PRS) that avoids standard-of-care (SOC) prognostic signal for use in patients with urothelial cancer (UC) by Shepherd, Jonathan, Mayhew, Gregory, Guo, John, Beebe, Kirk, Eisner, Joel Robert, Milburn, Michael Vance

“…549 Background: Immune checkpoint inhibition (ICI) shows great promise, including approval of pembrolizumab, nivolumab and avelumab in urothelial cancer (UC)…”
Get full text

Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC) by Pappan, Kirk L., Mayhew, Gregory, Davison, James M., Shibata, Yoichiro, Eisner, Joel Robert, Beebe, Kirk, Milburn, Michael Vance

“…548 Background: Interest in FGFR-targeted (FGFRi) therapies for UC or pan-tumor use is growing (ongoing clinical studies include erdafitinib (NCT05316155;…”
Get full text

Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats by Moore, William R., Sharp, Matthew, Eisner, Joel Robert, Bell, Caroline, Freeman, Stuart, Leesnitzer, Tony, Schotzinger, Robert

“…Abstract only 160 Background: Oral AA is a standard of care for metastatic prostate cancer. The recommended daily AA 1000 mg dose produces high peak and low…”
Get full text

Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model by Moore, William R., Sharp, Matthew, Bell, Caroline, Freeman, Stuart, Parr, Alan, Eisner, Joel Robert, Schotzinger, Robert

“…Abstract only 78 Background: Oral abiraterone acetate (AA) is a standard of care for castration-resistant (CRPC) and castration-sensitive prostate cancer…”
Get full text

Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide by Avitia, Jose W., Shore, Neal D., Nordquist, Luke T., Malone, Ryan J., Morris, David, Peer, Cody J., Richardson, William, Schmidt, Keith Thomas, Figg, William Douglas, Walling, Jacqueline M., McDougall, Katherine, Eisner, Joel Robert, Moore, William R., Tutrone, Ronald F.

“…140 Background: PRL-02 is a novel long-acting intramuscular (IM) depot injection prodrug of abiraterone (AA) that was designed to provide better safety through…”
Get full text

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer by Shore, Neal D., Avitia, Jose W., Bailen, James L., Nordquist, Luke T., Richardson, William, Peer, Cody J., Figg, William Douglas, Walling, Jacqueline M., Eisner, Joel Robert, Sharp, Matthew, Schotzinger, Robert J., Moore, William R., Tutrone, Ronald F.

“…TPS5117 Background: PRL-02 is a long-acting IM depot injection of abiraterone decanoate, a novel prodrug of abiraterone delivered through the lymphatic system…”
Get full text

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer by Avitia, Jose W., Tutrone, Ronald F., Shore, Neal D., Bailen, James L., Nordquist, Luke T., Richardson, William, Peer, Cody J., Figg, William Douglas, Walling, Jacqueline M., Eisner, Joel Robert, Sharp, Matthew, Schotzinger, Robert, Moore, William R.

“…141 Background: PRL-02 (abiraterone decanoate) is a novel, long-acting IM depot prodrug of abiraterone. In non-clinical models, PRL-02 provided high and…”
Get full text

Molecular characterization of advanced muscle invasive bladder cancer (MIBC): Comparison of low-input targeted RNA sequencing (RNAseq) strategies by Shibata, Yoichiro, Uronis, Joshua M., Conroy, Jeffrey M., Glenn, Sean, Guo, John, Mayhew, Gregory, Eisner, Joel Robert, Milburn, Michael Vance

“…Abstract only 564 Background: 5-year survival for advanced MIBC is poor (~5%), but newer targeted agents (e.g., PD-1/PD-L1 or FGFR) have improved survival over…”
Get full text

Detailed immunogenomic analysis of high dose IL-2 pharmacodynamic effects: A benchmark for next-generation IL-2-based immunotherapies by Beebe, Kirk, Eisner, Joel Robert, Shibata, Yoichiro, Davison, James M, Guo, John, Farhangfar, Carol J., Farhangfar, Farhang, Uronis, Joshua M., Mooney, Jill, Milburn, Michael Vance, Foureau, David, White, Richard L., Amin, Asim, Milla, Marcos E

“…e16501 Background: High-dose interleukin-2 (HD IL-2) was the first approved immune-oncology (IO) agent based on proven clinical efficacy in renal cell…”
Get full text

Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers by Lopez, Juanita Suzanne, Haefliger, Simon, Plummer, Ruth, Clement, Paul M., Laubli, Heinz Philipp, Roth, Patrick, Evans, T.R. Jeffry, Brazil, Lucy, Tabatabai, Ghazaleh, Wick, Antje, Yau, Wing Hing Hing, Wunderlich, Benjamin, Beebe, Kirk, Eisner, Joel Robert, Engelhardt, Marc, Kaindl, Thomas, Lane, Heidi A, Hau, Peter, Hundsberger, Thomas, Steinbach, Joachim

“…2044 Background: Lisavanbulin (BAL101553, prodrug of BAL27862) destabilizes microtubules and promotes tumor cell death by modulating the spindle assembly…”
Get full text

The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma by Tiu, Crescens Diane, Derby, Sarah, Haris, Noor Md, Welsh, Liam, Stansfeld, Anna, Hundsberger, Thomas, Roth, Patrick, König, Fatima, Eisner, Joel Robert, Kleinschmidt, Malte, Anderson, Stephanie, Bachmann, Felix, Lane, Heidi A, Engelhardt, Marc, Kaindl, Thomas, Litherland, Karine, Stan, Alexandru C, Evans, T.R. Jeffry, Plummer, Elizabeth Ruth, Lopez, Juanita Suzanne

“…Abstract only TPS2068 Background: Lisavanbulin (BAL101553, prodrug of BAL27862) is a novel tumor checkpoint controller that promotes tumor cell death by…”
Get full text

Once-nightly (QD) dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464 in patients with CRPC by Shore, Neal D., Nordquist, Luke T., Gupta, Shilpa, Fleming, Mark T., Berry, William R., Zhang, Jingsong, Kurman, Michael R, Eisner, Joel Robert, Moore, William R.

“…Abstract only 343 Background: VT-464 is an oral, CYP17-L inhibitor and non-clinically an antagonist of the AR and its variants associated with clinical…”
Get full text

Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC) by Bardia, Aditya, Dacosta, Noshir Anthony, Gabrail, Nashat Y., Lemon, Stephen, Danso, Michael A., Ali, Haythem Y., Fleming, Ronald Alan, Kurman, Michael R, Eisner, Joel Robert, Moore, William Richard, Gucalp, Ayca, Traina, Tiffany A.

“…Abstract only…”
Get full text

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01 by Gucalp, Ayca, Danso, Michael A., Elias, Anthony D., Bardia, Aditya, Ali, Haythem Y., Potter, David, Gabrail, Nashat Y., Haley, Barbara B., Khong, Hung T., Riley, Elizabeth Carloss, Ervin, Leigh, Eisner, Joel Robert, Baskin-Bey, M.D., Edwina, Moore, William Richard, Traina, Tiffany A.

“…Abstract only 1102 Background: Seviteronel (Sevi), an oral selective CYP17-lyase and AR inhibitor that blocks testosterone and estradiol production and…”
Get full text

The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC by De Bono, Johann Sebastian, Pezaro, Carmel Jo, Gillessen, Silke, Shore, Neal D., Nordquist, Luke T., Efstathiou, Eleni, Araujo, John C., Berry, William R., Liu, Glenn, Vogelzang, Nicholas J., Omlin, Aurelius Gabriel, Schotzinger, Robert J., Eisner, Joel Robert, Moore, William R.

“…Abstract only 187 Background: VT-464 is an oral, non-steroidal inhibitor of CYP17-L and an antagonist of androgen receptor (AR) variants F876L and T877A which…”
Get full text

The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models by Moore, William R., Maity, Sankar N., Eisner, Joel Robert, Garvey, Edward P., Hoekstra, William J., Titus, Mark Anton, Logothetis, Christopher, Araujo, John C., Efstathiou, Eleni, Schotzinger, Robert J.

“…Abstract only 158 Background: CRPC typically responds to anti-androgen therapy but resistance is common. CYP17 inhibitors that block lyase (L) and not…”
Get full text

Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC by Nordquist, Luke T., Shore, Neal D., De Bono, Johann S., Gupta, Shilpa, Berry, William R., Gillessen, Silke, Liu, Glenn, Vogelzang, Nicholas J., Efstathiou, Eleni, Fleming, Mark T., George, Daniel J., Araujo, John C., Zhang, Jingsong, Kurman, Michael R, Eisner, Joel Robert, Moore, William R.

“…Abstract only 273 Background: VT-464 is an oral, CYP17-L inhibitor and non-clinically an antagonist of the AR and its variants associated with clinical…”
Get full text

VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC) by Eisner, Joel Robert, Abbott, David H, Bird, Ian M, Rafferty, Stephen W, Moore, William R, Schotzinger, Robert J

“…Abstract only e15167 Background: CYP17 is a single protein with two distinct enzyme activities, 17 α-hydroxylase (hydroxylase) and 17,20-lyase (lyase)…”
Get full text

VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC) by Eisner, Joel Robert, Abbott, David H, Bird, Ian M, Rafferty, Stephen W, Moore, William R, Schotzinger, Robert J

“…Abstract only 198 Background: CYP17 is a single protein with two distinct enzyme activities, 17 α-hydroxylase (hydroxylase) and 17,20-lyase (lyase). Reduction…”
Get full text